Halozyme Therapeutics, Inc. (HALO) Stock

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. is led by CEO Helen I. Torley, employs 423 people, headquartered in San Diego, US, publicly traded since 2004.

Halozyme Therapeutics, Inc. (HALO) stock trades at $125.63 with a market capitalization of $14.26B. The stock is valued at a price-to-earnings (P/E) ratio of 30.77, price-to-book of 88.49, price-to-sales of 7.72. Over the past 52 weeks the stock has ranged between $61.23 and $125.66, and currently trades at or near its 52-week high.

On profitability, Halozyme Therapeutics, Inc. generates a return on equity (ROE) of 180.63%, above the typical market range of roughly 12-15%, return on capital employed of 42.30%, an operating margin of 56.96%, a net profit margin of 24.86%.

Halozyme Therapeutics, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Halozyme Therapeutics, Inc. reported revenue of $147.0M rising to $1.4B, a change of +850.3% across 10 years. Compounded, revenue has grown 39.1% a year over five years, 28.4% over three, 37.6% over the last twelve months. Net profit rose to $317.0M.

Operating margin went from -56.7% in 2016 to 58.5% in 2025, a gain of 115.2 percentage points. The most recent net margin is 24.86%. On a trailing twelve-month basis to Jun '26, revenue is $1.7B and net profit $413.0M.

Borrowings rose from $217.0M to $2.1B, cash from operations was $652.0M in the latest year, positive in 7 of the last 10.

Return on equity has averaged 285.6% over five years, and was 646.9% in the most recent year.

The share price itself has compounded at 10.2% a year over five years, 24.3% over three, 26.4% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Halozyme Therapeutics, Inc. (HALO) — frequently asked questions